Gaudium IVF and Women Health Ltd
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India.[1]
- Market Cap ₹ 692 Cr.
- Current Price ₹ 95.1
- High / Low ₹ 99.8 / 69.2
- Stock P/E 35.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 48.6 %
- ROE 52.2 %
- Face Value ₹ 5.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 55.4%
Cons
- Company has high debtors of 170 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 37 | 44 | 48 | 71 | |
| 23 | 24 | 28 | 42 | |
| Operating Profit | 14 | 20 | 19 | 29 |
| OPM % | 37% | 46% | 41% | 41% |
| 0 | 0 | 0 | 0 | |
| Interest | 1 | 0 | 1 | 2 |
| Depreciation | 1 | 1 | 2 | 2 |
| Profit before tax | 12 | 18 | 17 | 25 |
| Tax % | 26% | 26% | 38% | 25% |
| 9 | 14 | 10 | 19 | |
| EPS in Rs | 89.17 | 136.54 | 104.22 | 3.12 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 29% |
| TTM: | 85% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 55% |
| Last Year: | 52% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 0.99 | 31 | 31 |
| Reserves | 8 | 22 | 26 | 16 | 28 |
| 6 | 12 | 17 | 21 | 24 | |
| 3 | 2 | 7 | 22 | 24 | |
| Total Liabilities | 18 | 37 | 51 | 89 | 107 |
| 4 | 18 | 19 | 18 | 30 | |
| CWIP | 0 | 0 | 0 | 7 | 0 |
| Investments | 0 | 0 | 0 | 5 | 5 |
| 14 | 18 | 32 | 58 | 72 | |
| Total Assets | 18 | 37 | 51 | 89 | 107 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -1 | 24 | 3 | 9 | |
| -1 | -16 | -5 | -15 | |
| 3 | 5 | -1 | 2 | |
| Net Cash Flow | 0 | 13 | -3 | -5 |
| Free Cash Flow | -2 | 9 | 1 | -0 |
| CFO/OP | 13% | 141% | 27% | 46% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 65 | 8 | 104 | 170 |
| Inventory Days | 29 | 111 | 168 | 175 |
| Days Payable | 114 | 77 | 62 | 338 |
| Cash Conversion Cycle | -20 | 41 | 210 | 7 |
| Working Capital Days | 61 | -52 | -15 | 44 |
| ROCE % | 76% | 45% | 49% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
1d - Compliance certificate under Regulation 74(5) for quarter ended March 31, 2026; no rematerialisation requests.
-
Gaudium IVF And Women Health Limited Has Updated The Exchange On The Query Received From BSE Limited Vide Its Email Dated April 07 2026 Seeking Additional Details For Corporate Announcement Dated April 06 2026 Filed Under Regulation 30 Of SEBI (LODR) Regu
7 Apr - Bombay High Court disposed Neomile petition on April 2, 2026; Justice Nitin Jamdar appointed sole arbitrator.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 (Listing Regulations)
6 Apr - Bombay High Court disposed IPO-related petition; Justice Nitin Jamdar appointed sole arbitrator on April 2, 2026.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 Apr - April 1, 2026: Gaudium IVF introduces AI-driven SiD and ERICA with IVF 2.0 partnership; inaugurated by Minister Gadkari.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulation 2015 ( "Listing Regulations")
1 Apr - Neomile files Section 9 arbitration seeking interim relief of Rs29,20,50,000 over alleged IPO advisory fees.
Business Profile[1][2]
The company operates in the Assisted Reproductive Technology (ART) and IVF segment in India, following a hub-and-spoke model across 30+ locations (7 hubs and 28 spokes). It also runs a 15-bed day-care hospital in Janakpuri (Delhi NCR) and operates an in-house pharmacy through its wholly owned subsidiary, Gaudium International Pvt. Ltd.